Atossa Therapeutics, Inc. (NASDAQ:ATOS – Get Free Report) Director Jonathan Finn bought 25,000 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were purchased at an average cost of $1.77 per share, with a total value of $44,250.00. Following the purchase, the director now directly owns 25,000 shares of […]
Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Chadwick wins Wildwood Rock Extreme, Matt Moss injury update, Wilson wins Japan MX final, Australian Women second at ISDE 2023, Bou wraps up X-Trial in Vendée, 2024 Australian ProMX opener confirmed, 2024 FIM Oceania Women’s Motocross Cup, Bathurst Long Track Masters returns in 2024, Yamaha sign Lotte van Drunen, GASGAS EMX250 team revealed, 2024 FIM E-Xplorer World Cup calendar, Al-Balooshi wins Dubai Baja & FIM Bajas World Cup title, 2023 ISDE Wrap Up from Argentina, 2023 FOX Australian Supercross Round Two Newcastle Wrap
Atossa Therapeutics Inc (NASDAQ:ATOS) announced it has appointed Jonathan Finn to its board of directors, effective November 8, 2023. The company noted that.